Skip to main content
. 2024 Jul 4;8(16):4359–4369. doi: 10.1182/bloodadvances.2024012923

Table 3.

Maternal pregnancy and birth outcomes

Intervention (n = 17) Control (n = 17) Comparison
RR (95% CI) Difference (95% CI)
Antenatal admission for any reason, n (%) 7 (41.2%) 10 (58.8%) 0.70 (0.35-1.40)
Inpatient nights for any reason, mean (SD) 4.71 (4.50) 7.30 (8.93) −2.59 (−9.64 to 4.47)
Antenatal admission for SCD, n (%) 6 (35.3%) 10 (58.8%) 0.60 (0.28-1.28)
Inpatient nights for SCD, mean (SD) 3.33 (2.50) 7.10 (9.05) −3.77 (−10.35 to 2.81)
Sickle cell crisis during pregnancy, n (%) 8 (47.1%) 13 (76.5%) 0.62 (0.35-1.09)
Severe crisis during pregnancy, n (%) 6 (35.3%) 8 (47.1%) 0.75 (0.33-1.70)
Acute chest syndrome, n (%) 0 (0.0%) 1 (5.9%) -
Preeclampsia, n (%) 0 (0.0%) 2 (11.8%) -
Venous/pulmonary embolism in pregnancy, n (%) 1 (5.6%) 0 (0.0%) -
Onset of labor
 Spontaneous, n (%) 0 (0.0%) 2 (11.8%) -
 Induced, n (%) 8 (47.1%) 10 (58.8%) -
 Cesarean delivery, n (%) 9 (52.9%) 5 (29.4%) -
Emergency cesarean, n (%) 3 (17.6%) 1 (5.9%) 3.00 (0.35-26.04)
Elective cesarean, n (%) 10 (58.8%) 9 (52.9%) 1.11 (0.61-2.02)
Postpartum transfusion, n (%) 2 (11.8%) 6 (37.5%) 0.31 (0.07-1.33)
Proposed composite end point for TAPS3§, n (%) 10 (58.8%) 15 (88.2%) 0.67 (0.43-1.03)

Intervention arm consists of serial prophylactic exchange transfusion; control arm consists of standard care. One participant from the intervention arm was excluded from the analysis because of a spontaneous abortion occurring <16 weeks before the first procedure.

Outcome contributes to proposed composite end point for TAPS3.

Among those with at least 1 admission.

Defined as sickle cell crisis requiring inpatient admission.

§

Proposed composite end point for future definitive study, ≥1 of: admission for SCD, sickle cell crisis (any report), acute chest syndrome, preeclampsia, venous/pulmonary embolism, and emergency cesarean delivery.